Sinovac Set to Move Listing to NASDAQ

| About: Sinovac Biotech, (SVA)

Sinovac Biotech Ltd. (NASDAQ:SVA) will move the home for its stock listing from the NYSE Amex to the NASDAQ Global Market. The reason given for the change was “greater liquidity.” Target day for the transfer is November 16. Although most NASDAQ companies use a four-letter symbol, Sinovac will be allowed to keep its current three-letter identifier, SVA, so the new listing will not have a great effect on most investors.

Sinovac makes vaccines, most of which are sold in China. Its Healive vaccine for hepatitis B is the company’s mainstay product, though it has generated a great deal of news during the last six months with its H1N1 swine flu vaccine and the spillover of interest into its seasonal flu vaccine as well.

Disclosure: none.

About this article:

Tagged: , Biotechnology, China
Problem with this article? Please tell us. Disagree with this article? .